CDNA at a glance
CareDx, Inc. (CDNA, SEC CIK 1217234) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CareDx, Inc. (CDNA) reported revenue of $379.8 million (up 13.8% from FY2024) and a net loss of $21.4 million. Diluted EPS was -$0.40.
- As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding CareDx, Inc. (CDNA) shares worth $1.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Riggsbee Richard Bryan on November 16, 2026 of 800 shares at $75.95 per share.
- In the last 90 days, CDNA insiders reported 0 open-market purchases ($0) and 20 open-market sales ($6.8M) on Form 4, a net sale of $6.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $379.8M
- +13.8% vs prior year
- Insiders · 90 days
- 0 buys · 20 sells
- Net −$6.8M
- 13F holders
- 30 funds
- $1.5B · −1 vs prior quarter
- Latest 8-K
- Oct 29, 2026
- Item 7.01 · Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Specialized molecular diagnostic testing and digital pharmacy solutions for transplant patients
- Expanded patient and digital solutions revenue by 31%, driven by pharmacy sales growth and wider Ottr software deployment
- Strategic share repurchase programs totaling $88 million in 2025, reflecting confidence despite net loss of $21 million
- Testing services volume increased 14% to approximately 200,000 tests, with overall revenue growth of 14% to $380 million
- Noteworthy litigation expense reversal in 2024 due to favorable patent ruling, partially offset by 2025 Securities Class Action settlement
Risk Factors
- MolDX/Noridian Proposed LCD revision may reduce reimbursement, impose utilization limits, and introduces bundled payment, with final decision due within 365 days from July 17, 2025
- Medicare reimbursement risk: 46% of testing revenue from Medicare, with AlloSure Kidney 2026 fee reduced by $88 to $2,753 per test after CMS crosswalk decision
- Dependency on single California lab facility; if inoperable, inability to perform core tests AlloSure Kidney, AlloMap Heart, HeartCare, and AlloSure Lung
- Competitive risk from rapid technological evolution in transplantation diagnostics, could render CareDx’s AlloSure and AlloMap tests obsolete
- Concentration risk around Medicare Advantage payer dispute over denied and recouped claims, creating financial uncertainty and potential repayment obligations
Management Discussion & Analysis
- Revenue recognition includes testing services, product sales, patient and digital solutions; testing revenue reduced by $3.5M refund reserve in 2025
- No profitability or margin figures disclosed in the provided text
- Management sees no goodwill or intangible asset impairments as of Dec 31, 2025; foreign operations risks noted but no quantified impact or guidance
AI summary of the CDNA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $139.4M, up 39% YoY from $100.1M
- Testing Services best performer: $119.2M, up 65% YoY; Product revenue worst, $0 vs $12.5M
- Operating margin 5.8% vs (0.2)% YoY; net income $19.3M vs $1.7M
- Operating cash flow $13M; nine-month cash $250.5M, with $164.8M sale proceeds and $145.8M Naveris acquisition
- NavDx outlook sensitive to payer coverage, clinician adoption, competition and Naveris integration; up to $100.0M contingent consideration tied to 2026 and 2027 revenue milestones
Risk Factors
- Newly emphasized AI risk: healthcare AI may produce inaccurate or biased outputs, triggering regulatory scrutiny, product complaints, recalls, or liability claims
- Medicare reimbursement risk: 2027 preliminary rates show AlloSure rising from $2,753 to $2,840, but final CMS rates remain subject to revision
- Regulatory compliance risk: FDA LDT oversight remains uncertain after 2025 rule reversal, potentially requiring additional studies and PMA or 510(k) submissions
- Competitive risk: NavDx faces larger ctDNA competitors with broader oncology menus, stronger payer relationships, and greater resources
- Financial risk: cash and equivalents totaled $250.5 million against a $486.2 million accumulated deficit, with additional capital potentially required
AI summary of the CDNA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation current as of September 30, 2026
- Investor materials available on CareDx’s website
Item EX-99.1: Item EX-99.1
- Q3 revenue $139.4M, up 39% YoY, led by Testing Services growth of 65% to $119.2M
- GAAP net income $19.3M, margin 14%, versus $1.7M and 2% in Q3 2025
Item 2.02: Results of Operations and Financial Condition
- CareDx announced financial results for the quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed quarterly results and management commentary
Item 2.01: Completion of Acquisition or Disposition of Assets
- CareDx completed its acquisition of Naveris, expanding its portfolio through the acquired Delaware-based company
- Amendment adds Naveris historical financial statements and Article 11 pro forma information
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation current as of June 30, 2026
- Investor-relevant business information available on CareDx’s website
Item 2.02: Results of Operations and Financial Condition
- CareDx announced financial results for the quarter ended June 30, 2026
- Full results and management commentary appear in Exhibit 99.1, the accompanying press release
Item EX-99.1: Item EX-99.1
- Q2 revenue $132M, up 52% YoY, with Testing Services revenue up 61% to $100M
- Adjusted EBITDA $25M, up from $5M, with margin reaching 19% from 6%
AI summaries of CDNA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CDNA
Don't miss the next CDNA filing
- Alerts as it files. A push when CDNA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CDNA, by share count.
- Ask anything. An AI agent that reads every CDNA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Riggsbee Richard Bryan | Sell | Nov 16, 2026 | 800 | $75.95 |
| Riggsbee Richard Bryan | Sell | Nov 16, 2026 | 1,667 | $74.74 |
| Riggsbee Richard Bryan | Sell | Nov 16, 2026 | 400 | $77.02 |
| Riggsbee Richard Bryan | Sell | Nov 16, 2026 | 2,418 | $74.02 |
| Kennedy Keith | M | Nov 12, 2026 | 2,097 | $29.43 |
| Kennedy Keith | Sell | Nov 12, 2026 | 800 | $78.78 |
| Kennedy Keith | Sell | Nov 12, 2026 | 1,297 | $79.61 |
| Goldberg Michael | Sell | Nov 12, 2026 | 2,229 | $79.85 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $280.3M | $333.8M | $379.8M |
| Operating Income | -$203.4M | $40.8M | -$30.8M |
| Net Income | -$190.3M | $52.5M | -$21.4M |
| Op. Margin | -72.5% | 12.2% | -8.1% |
| Net Margin | -67.9% | 15.7% | -5.6% |
| Balance Sheet | |||
| Total Assets | $466.8M | $491.1M | $413.2M |
| Equity | $261.3M | $378.4M | $303.1M |
| ROE | -72.8% | 13.9% | -7.0% |
| Per Share | |||
| EPS | $-3.54 | $0.93 | $-0.40 |
| Cash Flow | |||
| Operating CF | - | $38.0M | $42.0M |
Source: XBRL data in CareDx, Inc. (CDNA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CDNA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 30 | $1.47B |
| Q2 2026 | 31 | $595.0M |
| Q1 2026 | 30 | $351.2M |
| Q4 2025 | 28 | $390.4M |
| Q3 2025 | 28 | $301.5M |
| Q2 2025 | 29 | $464.9M |
| Q1 2025 | 27 | $361.9M |
| Q4 2024 | 23 | $398.0M |
- Citadel Advisors LLC+1.03M (+962%)
- Franklin Resources+916.9K (+1333%)
- Goldman Sachs Group+231.7K (+33%)
- Millennium Management+184.7K (+250%)
- State Street Corp+154.2K (+6%)
- ARK Investment Management−344.5K (-18%)
- Morgan Stanley−329.8K (-43%)
- Two Sigma Investments−203.7K (-51%)
- Invesco Ltd−176.0K (-39%)
- Vanguard Portfolio Management LLC−136.1K (-14%)
- FMR LLC (Fidelity)−253.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 226 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CDNA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
Related Health Care companies
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
- NTRA · Natera IncServices-Medical Laboratories
CDNA SEC filings: frequently asked questions
Are CDNA insiders buying or selling?
In the last 90 days, CareDx, Inc. (CDNA) officers, directors and 10% owners reported no open-market purchases and 20 open-market sales worth $6.8 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CDNA stock?
As of September 30, 2026, the largest CareDx, Inc. (CDNA) holders among the 13F filers tracked by SignalX were BlackRock ($316.7 million), State Street Corp ($170.5 million), Vanguard Capital Management LLC ($142.6 million), ARK Investment Management ($104.6 million), Franklin Resources ($84.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CDNA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CareDx, Inc. (CDNA) reported revenue of $379.8 million (up 13.8% from FY2024) and a net loss of $21.4 million. Diluted EPS was -$0.40. The figures come from the XBRL data in the 10-K.
What are the main risks in CDNA's latest 10-K?
In the 10-K filed February 25, 2026, CareDx, Inc. (CDNA) flagged: MolDX/Noridian Proposed LCD revision may reduce reimbursement, impose utilization limits, and introduces bundled payment, with final decision due within 365 days from July 17, 2025. Medicare reimbursement risk: 46% of testing revenue from Medicare, with AlloSure Kidney 2026 fee reduced by $88 to $2,753 per test after CMS crosswalk decision. (AI summary of the Risk Factors section.)
What did CDNA report in its latest 8-K?
CareDx, Inc. (CDNA) filed an 8-K on October 29, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Updated corporate presentation current as of September 30, 2026.
What are the latest CDNA SEC filings?
CareDx, Inc. (CDNA) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 18, 2026.
What is CDNA's SEC CIK number?
CareDx, Inc. (CDNA)'s SEC Central Index Key (CIK) is 1217234. EDGAR lists every CDNA filing under that number.
Ask anything about CDNA
The research agent reads CDNA's filings, financials, insider trades and 13F holders, then answers with sources.